ADVOCACY
-
CHS reacts to Health Canada decision on relaxing donor selection criteria
April 28, 2022 (Montreal) – “The Canadian Hemophilia Society (CHS) is disappointed that Health Canada has not followed our advice regarding the changes to donor...
-
The 10 key takeaways from CHS advocacy efforts to obtain access to emicizumab (Hemlibra)
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...
-
Letter to the Embassy of the Russian Federation in Canada
Please CLICK HERE to read the letter sent to the Russian Ambassador in Canada by the Canadian Hemophilia Society and the World Federation of Hemophilia...
-
Update on access to coagulation products for hemophilia A and B
by David Page, CHS National Director of Health Policy Access to a wide range of coagulation products is expanding in the provinces and territories served by...
-
Has the bleeding disorder world fundamentally changed?
by David Page, CHS National Director of Health Policy Given recent advances in therapies for inherited bleeding disorders, especially hemophilia A and B, I have...